SAV-CT01
Status:Completed
Phase:I
Principal Investigator(s):Anthony M Mills, M.D.; Stefan Schneider, M.D.
Objective:To assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
Description
Mode of Delivery
ARMsExperimental
Official Code:
NCT01546818
Trial Sponsors:
Living Hope Clinical Foundation, Sumagen
Start Date
End Date
March 1, 2012
November 30, 2013
Enrollment:33
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women